Literature DB >> 23001119

Propofol improves recovery of the isolated working hypertrophic heart from ischaemia-reperfusion.

Nicola King1, Madj Al Shaama, M-Saadeh Suleiman.   

Abstract

The general anaesthetic propofol shows promise in protecting normal hearts against various cardiac insults, but little is known about its cardioprotective potential in hypertrophic hearts. This study tested the hypothesis that propofol at a clinically relevant dose would enhance functional recovery in hypertrophic hearts following ischaemia. Hypertrophic hearts from spontaneously hypertensive rats and hearts from their normotensive controls, Wistar Kyoto Rats, were equilibrated in the working mode prior to global normothermic ischaemia. Reperfusion commenced with 10 min in Langendorff mode, followed by 30-min working reperfusion. Functional performance was measured throughout the working mode, whilst reperfusion damage was assessed from myocardial troponin I release during Langendorff reperfusion. Where used, 4 μg/ml propofol was added 10 min before ischaemia and was washed out 10 min into working reperfusion. An additional protocol investigated recovery of hearts protected by normothermic hyperkalaemic cardioplegic arrest. Following 20-min ischaemia, reperfusion damage was significantly worse in hypertrophic hearts compared to normal hearts, whilst addition of propofol to hypertrophic hearts significantly improved the aortic flow (31 ± 5.8 vs. 11.6 ± 2.0 ml/min, n = 6-7 ± SE, p < 0.05). Propofol also conferred significant protection following 30-min ischaemia where the recovery of cardiac output and stroke volume was similar to that for cardioplegia alone. Incubation with propofol improved the NADH/NAD(+) ratio in freshly isolated cardiomyocytes from hypertrophic hearts, suggesting possible improvements in metabolic flux. These findings suggest that propofol at the clinically relevant dose of 4 μg/ml is as effective as cardioplegic arrest in protecting hypertrophic hearts against ischaemia-reperfusion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23001119     DOI: 10.1007/s00424-012-1152-5

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  30 in total

1.  Protective effect of propofol and its relation to postoperation recovery in children undergoing cardiac surgery with cardiopulmonary bypass.

Authors:  Wen-fang Xia; Yu Liu; Qing-shan Zhou; Qi-zhu Tang; Han-dong Zou
Journal:  Pediatr Cardiol       Date:  2011-06-03       Impact factor: 1.655

2.  Comparison of the effects of propofol and midazolam on inflammation and oxidase stress in children with congenital heart disease undergoing cardiac surgery.

Authors:  Wen-fang Xia; Yu Liu; Qing-shan Zhou; Qi-zhu Tang; Han-dong Zou
Journal:  Yonsei Med J       Date:  2011-03       Impact factor: 2.759

3.  Age-dependent and hypoxia-related differences in myocardial protection during pediatric open heart surgery.

Authors:  H Imura; M Caputo; A Parry; A Pawade; G D Angelini; M S Suleiman
Journal:  Circulation       Date:  2001-03-20       Impact factor: 29.690

4.  Pharmacogenomic strain differences in cardiovascular sensitivity to propofol.

Authors:  Thomas A Stekiel; Stephen J Contney; Richard J Roman; Craig A Weber; Anna Stadnicka; Zeljko J Bosnjak; Andrew S Greene; Carol Moreno
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

5.  Specificity and properties of propofol as an antioxidant free radical scavenger.

Authors:  T R Green; S R Bennett; V M Nelson
Journal:  Toxicol Appl Pharmacol       Date:  1994-11       Impact factor: 4.219

Review 6.  Protection of the abnormal heart.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Dennis V Cokkinos
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

7.  The importance of myocardial amino acids during ischemia and reperfusion in dilated left ventricle of patients with degenerative mitral valve disease.

Authors:  A Venturini; R Ascione; H Lin; E Polesel; G D Angelini; M-S Suleiman
Journal:  Mol Cell Biochem       Date:  2009-04-11       Impact factor: 3.396

8.  Differences in cardiovascular sensitivity to propofol in a chromosome substitution rat model.

Authors:  Thomas A Stekiel; Craig A Weber; Stephen J Contney; Zeljko J Bosnjak
Journal:  Croat Med J       Date:  2007-06       Impact factor: 1.351

9.  Propofol is cardioprotective in a clinically relevant model of normothermic blood cardioplegic arrest and cardiopulmonary bypass.

Authors:  Kelvin H H Lim; Andrew P Halestrap; Gianni D Angelini; M-Saadeh Suleiman
Journal:  Exp Biol Med (Maywood)       Date:  2005-06

Review 10.  ROS and RNS signaling in heart disorders: could antioxidant treatment be successful?

Authors:  Igor Afanas'ev
Journal:  Oxid Med Cell Longev       Date:  2011-09-08       Impact factor: 6.543

View more
  6 in total

1.  Sevoflurane-Remifentanil Versus Propofol-Remifentanil Anesthesia During Noncardiac Surgery for Patients with Coronary Artery Disease - A Prospective Study Between 2016 and 2017 at a Single Center.

Authors:  Zhongliang Dai; Miao Lin; Yali Li; Wenli Gao; Ping Wang; Juan Lin; Zhenzhen Wan; Yuanxu Jiang
Journal:  Med Sci Monit       Date:  2021-08-21

2.  Propofol Inhibits Ischemia/Reperfusion-Induced Cardiotoxicity Through the Protein Kinase C/Nuclear Factor Erythroid 2-Related Factor Pathway.

Authors:  Shengqiang Li; Zhen Lei; Meng Zhao; Yonghao Hou; Di Wang; Xingli Xu; Xiaowen Lin; Jingxin Li; Shuhai Tang; Jingui Yu; Tao Meng
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

3.  Mammalian target of rapamycin inhibition attenuates myocardial ischaemia-reperfusion injury in hypertrophic heart.

Authors:  Lei-Lei Ma; Xin Ma; Fei-Juan Kong; Jun-Jie Guo; Hong-Tao Shi; Jian-Bing Zhu; Yun-Zeng Zou; Jun-Bo Ge
Journal:  J Cell Mol Med       Date:  2018-01-04       Impact factor: 5.310

4.  Pathology-related changes in cardiac energy metabolites, inflammatory response and reperfusion injury following cardioplegic arrest in patients undergoing open-heart surgery.

Authors:  Katie L Skeffington; Marco Moscarelli; Safa Abdul-Ghani; Francesca Fiorentino; Costanza Emanueli; Barnaby C Reeves; Prakash P Punjabi; Gianni D Angelini; M-Saadeh Suleiman
Journal:  Front Cardiovasc Med       Date:  2022-07-22

Review 5.  Preclinical multi-target strategies for myocardial ischemia-reperfusion injury.

Authors:  Yuqing Li; Yi Gao; Guangping Li
Journal:  Front Cardiovasc Med       Date:  2022-08-22

6.  Propofol protects the immature rabbit heart against ischemia and reperfusion injury: impact on functional recovery and histopathological changes.

Authors:  Makoto Shirakawa; Hajime Imura; Takashi Nitta
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.